Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease
Authors:
- Bartolome CelliBCBartolome Celli
- UPLIFT Study InvestigatorsUIUPLIFT Study Investigators
- 15 November 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 180 (10) , 948-955
Abstract
Rationale: In the 4-year UPLIFT trial, tiotropium improved lung function and health-related quality of life and decreased exacerbations compared with usual respiratory medications except inhaled anticholinergics in patients with chronic obstructive pulmonary disease (COPD). Mortality and its causes was a secondary endpoint in UPLIFT. Objectives: We describe the effect of tiotropium on survival and analyze differences between mortality during treatment and during follow-up of discontinued patients. Methods: This study involved a randomized, double-blind trial comparing tiotropium with placebo in patients with COPD (≥40 yr of age; postbronchodilator FEV1 ≤70%; FEV1/FVC ≤70%). Mortality was evaluated during treatment and with follow-up of discontinued patients. Cause of death was adjudicated by an endpoint committee. Measurements and Main Results: A total of 5,993 patients were randomized, 3,006 to placebo and 2,987 to tiotropium. While patients were receiving treatment, there were 792 deaths, with a lower risk in the tiotropium group (hazard ratio, 0.84; 95% confidence interval [CI], 0.73–0.97). Statistical significance was observed at the end of the protocol-defined treatment period (P = 0.034) but not 30 days thereafter (P = 0.086). Adjustment by GOLD stage, sex, age, baseline smoking behavior, and baseline respiratory medications subgroups did not alter the results of the analysis. The most common causes of death adjudicated by an independent end-point committee were lower respiratory, cancer, general disorders, and cardiac disorders. The hazard ratios for lower respiratory and cardiac mortality during treatment were 0.86 (95% CI, 0.68–1.09) and 0.86 (95% CI, 0.75–0.99), respectively. Conclusions: Treatment with tiotropium over 4 years is associated with decreased mortality, with the effect being most prominent in the cardiac and respiratory systems.Keywords
This publication has 31 references indexed in Scilit:
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPDChest, 2005
- Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEuropean Respiratory Journal, 2004
- Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes *Chest, 2003
- A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe EmphysemaNew England Journal of Medicine, 2003
- A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 2002
- Clinical Indications for Noninvasive Positive Pressure Ventilation in Chronic Respiratory Failure Due to Restrictive Lung Disease, COPD, and Nocturnal Hypoventilation—A Consensus Conference ReportChest, 1999
- Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1JAMA, 1994
- LONG TERM DOMICILIARY OXYGEN THERAPY IN CHRONIC HYPOXIC COR PULMONALE COMPLICATING CHRONIC BRONCHITIS AND EMPHYSEMAThe Lancet, 1981
- Continuous or Nocturnal Oxygen Therapy in Hypoxemic Chronic Obstructive Lung DiseaseAnnals of Internal Medicine, 1980